Medindia

X

Boston Scientific Announces Results for First Quarter Ended March 31, 2010

Tuesday, April 27, 2010 Corporate News J E 4
Advertisement
NATICK, Mass., April 26 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2010, as well as guidance for net sales and earnings per share (EPS) for the second quarter and full year 2010.

First quarter highlights (sales growth rates are at constant currency):

"It was a challenging quarter including a settlement to resolve long-standing litigation, and the CRM ship hold and product removal actions," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "However, the return of COGNIS® and TELIGEN® to the U.S. market -- coupled with exceptional cash flow and a strong cadence from our new product pipeline -- were positive factors."

The Cardiac Rhythm Management (CRM) ship hold and product removal actions created an adverse impact on both sales and earnings within the first quarter. The combination of the expected financial impact of these actions -- coupled with slower expected market growth -- caused a $1.8 billion write-down of goodwill associated with the Company's U.S. CRM business unit, which it acquired through the Guidant acquisition. This is a non-cash charge that has no impact on the Company's debt covenants. The amount of the charge is subject to finalization during the second quarter of 2010.

Net sales for the first quarter of 2010 were $1.960 billion, as compared to net sales of $2.010 billion for the first quarter of 2009. Excluding the impact of foreign currency and net sales from divested businesses, net sales decreased six percent as compared to the prior period.

Worldwide CRM net sales for the first quarter -- on a reported basis -- were as follows:

Worldwide coronary stent system net sales for the first quarter -- on a reported basis -- were as follows:

Reported net loss for the first quarter of 2010 was $1.589 billion, or $1.05 per share. Reported results included goodwill and intangible asset impairment charges; acquisition- and restructuring-related net credits; and amortization expense (after-tax) of $1.840 billion, or $1.21 per share, which consisted of:

Adjusted net income for the first quarter of 2010, excluding these net charges, was $251 million, or $0.16 per share.

Reported net loss for the first quarter of 2009 was $13 million, or $0.01 per share. Reported results included acquisition-, divestiture-, restructuring- and litigation-related net charges; discrete tax benefits, and amortization expense (after-tax) of $302 million, or $0.20 per share. Adjusted net income for the first quarter of 2009, excluding these net charges, was $289 million, or $0.19 per share.

Guidance for Second Quarter and Full Year 2010

The Company estimates net sales for the second quarter of 2010 of between $1.825 billion and $1.925 billion. Adjusted earnings, excluding restructuring and restructuring-related costs and amortization expense, are estimated to range between $0.06 and $0.10 per share. The Company estimates results on a GAAP basis of between a loss of $0.03 and income of $0.02 per share.

As a result of the ship hold and product removal actions involving the Company's ICDs and CRT-Ds during the quarter, the Company is revising estimates for the full year ending December 31, 2010. The Company now estimates net sales for the full year 2010 of between $7.6 billion and $8.0 billion. Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-related credits, restructuring and restructuring-related costs, and amortization expense, are estimated to range between $0.50 and $0.60 per share. The Company now estimates a net loss on a GAAP basis of between $1.00 and $0.88 per share.

Boston Scientific officials will be discussing these results with analysts on a conference call at 8:00 a.m. (ET) Tuesday, April 27. The Company will webcast the call to all interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, new product approvals and sales, regulatory compliance and product removal actions, our market position, cash flow, debt repayment, write-down of goodwill and other asset impairments, acquisitions and divestitures, restructuring activities and litigation charges. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measure most comparable to non-GAAP net income per share is GAAP net income per share. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the impact of foreign exchange, the Company converts actual current-period net sales from local currency to U.S. dollars using constant foreign exchange rates. The GAAP measure most comparable to this non-GAAP measure is growth rate percentages based on GAAP revenue. A reconciliation of this non-GAAP financial measure to the corresponding GAAP measure is included in the accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston Scientific

Management uses these supplemental non-GAAP measures to evaluate performance period over period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company's operating segments. The adjustments excluded from the Company's non-GAAP measures are consistent with those excluded from its reportable segments' measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company's chief operating decision maker and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management excluded as part of its non-GAAP measures for the three months ended March 31, 2010 and 2009 and for the forecasted three month period ending June 30, 2010 and full year ending December 31, 2010, as well as reasons for excluding each of these individual items:

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange may have limitations as analytical tools, and these non-GAAP measures should not be considered in isolation from or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are:

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

Boston Scientific compensates for the limitations on its non-GAAP financial measures by relying upon its GAAP results to gain a complete picture of the Company's performance. The non-GAAP numbers focus instead upon the core business of the Company, which is only a subset, albeit a critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure in the accompanying schedules, and Boston Scientific encourages investors to review these reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange in addition to the related GAAP measures provides investors greater transparency to the information used by Boston Scientific management for its financial and operational decision-making and allows investors to see Boston Scientific's results "through the eyes" of management. The Company further believes that providing this information better enables Boston Scientific's investors to understand the Company's operating performance and to evaluate the methodology used by management to evaluate and measure such performance.

-- Achieved sales of $1.960 billion and adjusted EPS of $0.16, reporting a GAAP loss of $1.05 per share -- Maintained leadership position in the global drug-eluting stent (DES) market with 45 percent share in the U.S., 43 percent share in Japan, and 38 percent share worldwide -- Launched the PROMUS® Everolimus-Eluting Coronary Stent System in Japan and received a $250 million acquisition-related milestone payment from Abbott Laboratories -- Increased worldwide Endoscopy sales nine percent -- Increased worldwide Urology and Women's Health sales six percent -- FDA advisory panel unanimously recommended approval of an expanded indication for the Company's cardiac resynchronization therapy defibrillators (CRT-Ds) -- Received FDA approval for the Express® LD Iliac Premounted Stent System for use in iliac arteries

SOURCE Boston Scientific Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
MarketsandMarkets: Global OLED Market Worth US$2.2...
S
Almost Family, Inc. to Report First Quarter 2010 F...